A 38-year-old man with MEN 1 syndrome presents with severe gastric ulcer disease refractory to standard proton pump inhibitor therapy. Endoscopy confirms multiple gastric and duodenal ulcers. Serum gastrin level is markedly elevated at 2500 pg/mL (normal <100). What is the drug of choice for long-term management of this gastrinoma?

Explanation

## Management of Gastrinoma in MEN 1 ### Pathophysiology of Gastrinoma Gastrinomas are neuroendocrine tumors that secrete excessive gastrin, leading to severe peptic ulcer disease. In MEN 1, gastrinomas are often multiple and malignant in 60–70% of cases. ### Drug of Choice: Proton Pump Inhibitors (PPIs) **Key Point:** Omeprazole (or other PPIs like lansoprazole, pantoprazole) is the first-line and long-term drug of choice for managing the acid hypersecretion in gastrinoma. **High-Yield:** PPIs are superior to H₂-receptor antagonists because they: - Provide more potent and sustained acid suppression (>90% reduction in gastric acid) - Achieve better healing of severe ulcers - Require lower doses and less frequent dosing than H₂-blockers - Allow better quality of life in long-term management ### Mechanism of Action Omeprazole irreversibly inhibits the H⁺/K⁺-ATPase pump in gastric parietal cells, reducing gastric acid secretion by ~90%. ### Clinical Management Strategy ```mermaid flowchart TD A[Gastrinoma diagnosed]:::outcome --> B[Measure gastrin level & pH]:::action B --> C[Start PPI therapy]:::action C --> D[Titrate dose to achieve gastric pH > 4]:::action D --> E[Assess for metastases]:::decision E -->|Localized| F[Consider surgical resection]:::action E -->|Metastatic| G[Continue PPI + chemotherapy consideration]:::action G --> H[Long-term PPI maintenance]:::outcome ``` ### Dosing in Gastrinoma - Omeprazole: typically 60–80 mg daily (much higher than standard GERD dosing) - Titrate to achieve intragastric pH > 4 and gastrin suppression - Some patients require doses up to 240 mg/day **Clinical Pearl:** The goal is to suppress gastric acid secretion sufficiently to heal ulcers and prevent complications, not necessarily to normalize gastrin levels (which may remain elevated). ### Why Not H₂-Blockers? Although famotidine was historically used, it is now considered second-line because: - Requires higher doses and more frequent dosing - Less effective acid suppression (60–70% reduction) - Inferior ulcer healing rates - Worse long-term control in severe gastrinoma **Warning:** Do not confuse medical management (PPI) with definitive treatment (surgical resection of the tumor). PPIs control symptoms; surgery aims for cure. ### Somatostatin Analogues Octreotide can suppress gastrin secretion in some patients but is not first-line for acid control. It may be used as adjunctive therapy in metastatic disease. [cite:Harrison 21e Ch 297]